^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) + Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
135O - A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced MIBC
Published date:
11/28/2022
Excerpt:
Hence the cCR rate is 100%....Neoadjuvant RC48-ADC combined with tislelizumab in patients with HER2 positive locally advanced MIBC initially shows satisfied efficacy and manageable toxicities.
